The promising field of regenerative medicine is thrilling as it can repair and restore organs for various debilitating diseases. Mesenchymal stem cells are one of the main components in regenerative medicine that work through the release of secretomes. By adopting the use of the secretome in cell-free-based therapy, we may be able to address the challenges faced in cell-based therapy. As one of the components of cell-free-based therapy, secretome has the advantage of a better safety and efficacy profile than mesenchymal stem cells. However, secretome has its challenges that need to be addressed, such as its bioprocessing methods that may impact the secretome content and its mechanisms of action in clinical settings. Effective and standardization of bioprocessing protocols are important to ensure the supply and sustainability of secretomes for clinical applications. This may eventually impact its commercialization and marketability. In this review, the bioprocessing methods and their impacts on the secretome profile and treatment are discussed. This improves understanding of its fundamental aspects leading to potential clinical applications.

再生医学的前景令人兴奋，因为它可以修复和恢复各种使人衰弱的疾病的器官。间充质干细胞是再生医学的主要成分之一，通过释放分泌蛋白发挥作用。通过在基于无细胞的治疗中采用分泌蛋白组，我们也许能够解决基于细胞的治疗中面临的挑战。作为无细胞疗法的组成部分之一，分泌组具有比间充质干细胞更好的安全性和有效性的优点。然而，分泌蛋白组有其需要解决的挑战，例如其生物加工方法可能会影响分泌蛋白组的内容及其在临床环境中的作用机制。生物加工方案的有效和标准化对于确保临床应用分泌蛋白组的供应和可持续性非常重要。这最终可能会影响其商业化和适销性。在这篇综述中，讨论了生物加工方法及其对分泌蛋白组概况和治疗的影响。这提高了对其基本方面的理解，从而带来潜在的临床应用。